Glenmark’s Favipiravir shows strong potential

Glenmark Pharmaceuticals share price moved up by 8.61% from its previous close of Rs 318.20 on talks of the drug maker becoming the first Indian company to develop an anti-retroviral (ARV), a class of drugs that is being touted as a potential treatment for coronavirus.

Glenmark has developed ARV Favipiravir that has shown positive results to treat the disease.

Faviparir has demonstrated good results against influenza viruses, including those that are oseltamivir-resistant, and has been approved in Japan and China.

Globally, it is either anti-malarial drug hydroxychloroquine, or anti-retrovirals/anti-virals like Favipiravir, Remdesivir and Lopinavir, that are increasingly being used for Covid treatment.

Glenmark has submitted its application to tbe Drugs Controller General of India (DCGI) for marketing approval of Favipiravir.

The Mumbai-based drug maker has developed the API in-house, which is believed to have been a big challenge as many firms are still trying to do so.

Once the approval is in place, the company will conduct trials on 60-100 patients and launch the drug.

Fujifilm of Japan sells the drug Favipiravir under the brand Avigan which has been approved in Japan since 2014 to treat influenza, and other viral strains that don’t respond to other therapies.

The drug which was earlier used to treat Ebola became off-patent last year, which implies that generic versions can possibly be launched anywhere in the world.
Glenmark’s Favipiravir shows strong potential

Glenmark Pharmaceuticals share price moved up by 8.61% from its previous close of Rs 318.20 on talks of the drug maker becoming the first Indian company to develop an anti-retroviral (ARV), a class of drugs that is being touted as a potential treatment for coronavirus.

Glenmark has developed ARV Favipiravir that has shown positive results to treat the disease.

Faviparir has demonstrated good results against influenza viruses, including those that are oseltamivir-resistant, and has been approved in Japan and China.

Globally, it is either anti-malarial drug hydroxychloroquine, or anti-retrovirals/anti-virals like Favipiravir, Remdesivir and Lopinavir, that are increasingly being used for Covid treatment.

Glenmark has submitted its application to tbe Drugs Controller General of India (DCGI) for marketing approval of Favipiravir.

The Mumbai-based drug maker has developed the API in-house, which is believed to have been a big challenge as many firms are still trying to do so.

Once the approval is in place, the company will conduct trials on 60-100 patients and launch the drug.

Fujifilm of Japan sells the drug Favipiravir under the brand Avigan which has been approved in Japan since 2014 to treat influenza, and other viral strains that don’t respond to other therapies.

The drug which was earlier used to treat Ebola became off-patent last year, which implies that generic versions can possibly be launched anywhere in the world.

Disclaimer –
This document is meant for the recipient only for use as intended and not for circulation. This document should not be reproduced or copied or made available to others. The information contained herein is from the public domain or sources believed to be reliable. While reasonable care has been taken to ensure that information given is at the time believed to be fair and correct and opinions based thereupon are reasonable, due to the very nature of research it cannot be warranted or represented that it is accurate or complete and it should not be relied upon as such. Also above note is not a recommendation to Buy or SELL and is only a view based on facts and figures and we will be in no way responsible for any losses incurred by anyone who uses this information to either trade or invests securities mentioned herein.